Related Experiment Video
Updated: Feb 24, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
16.7K
Gynecologic melanomas: A clinicopathologic and molecular analysis
Aaron M Udager1, Nora K Frisch1, Linda J Hong2
1Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
Gynecologic Oncology
|August 29, 2017
Summary
Gynecologic melanomas (MOGS) are aggressive, particularly non-vulvar types, with poor outcomes. Few targeted therapies exist for these rare MOGS, highlighting a critical unmet need.
Area of Science:
- Gynecologic Oncology
- Dermatopathology
- Cancer Genomics
Background:
- Melanoma originating from gynecologic sites (MOGS) is rare, aggressive, and poorly understood.
- Vulvar and non-vulvar MOGS exhibit distinct clinicopathologic features and outcomes.
- MOGS generally lack BRAF mutations, unlike cutaneous melanomas.
Purpose of the Study:
- To analyze the clinicopathologic and molecular characteristics of MOGS.
- To compare vulvar and non-vulvar MOGS.
- To identify potential therapeutic targets in MOGS.
Main Methods:
- Retrospective analysis of 59 MOGS cases over 28 years.
- Statistical assessment of clinicopathologic features and Cox regression for outcomes.
- Sanger sequencing for mutations in BRAF, KIT, NRAS, and CTNNB1.
Main Results:
- Non-vulvar MOGS (vagina/cervix) show high-risk features: increased thickness, ulceration, positive margins, and lymph node metastasis.
- Non-vulvar MOGS have poor long-term outcomes, independent of stage and nodal status.
- Low overall mutation rate; KIT mutations (exon 11) are relatively enriched.
Conclusions:
- Non-vulvar MOGS are aggressive with poor prognosis.
- Limited targeted therapy options are available for MOGS patients.
- Further research into MOGS biology and treatment is warranted.
